Browsing by Subject "Costs and Cost Analysis"
Now showing items 1-17 of 17
-
An evaluation of patient self-testing competency of prothrombin time for managing anticoagulation: pre-randomization results of VA Cooperative Study #481--The Home INR Study (THINRS).
(Journal of thrombosis and thrombolysis, 2010-10)Prior studies suggest patient self-testing (PST) of prothrombin time (PT) can improve the quality of anticoagulation (AC) and reduce complications (e.g., bleeding and thromboembolic events). "The Home INR Study" (THINRS) ... -
Bundled Payment and Care of Acute Stroke: What Does it Take to Make it Work?
(Stroke, 2015-05) -
Burning a hole in the budget: tobacco spending and its crowd-out of other goods.
(Appl Health Econ Health Policy, 2004)Smoking is an expensive habit. Smoking households spend, on average, more than $US1000 annually on cigarettes. When a family member quits, in addition to the former smoker's improved long-term health, families benefit because ... -
Cost efficiency of anticoagulation with warfarin to prevent stroke in medicare beneficiaries with nonvalvular atrial fibrillation.
(Stroke, 2011-01)<h4>Background and purpose</h4>in controlled trials, anticoagulation with warfarin reduces stroke risk by nearly two thirds, but the benefit has been less pronounced in clinical practice. This report describes the extent ... -
Cost of capital to the hospital sector.
(J Health Econ, 1988-03)This paper provides estimates of the cost of equity and debt capital to for-profit and non-profit hospitals in the U.S. for the years 1972-83. The cost of equity is estimated using, alternatively, the Capital Asset Pricing ... -
Cost of innovation in the pharmaceutical industry.
(J Health Econ, 1991-07)The research and development costs of 93 randomly selected new chemical entities (NCEs) were obtained from a survey of 12 U.S.-owned pharmaceutical firms. These data were used to estimate the pre-tax average cost of new ... -
Data Sharing at a Crossroads.
(N Engl J Med, 2016-09-22) -
Does Medicaid pay more to a program of all-inclusive care for the elderly (PACE) than for fee-for-service long-term care?
(J Gerontol A Biol Sci Med Sci, 2013-01)BACKGROUND: In rebalancing from nursing homes (NHs), states are increasing access of NH-certified dually eligible (Medicare/Medicaid) patients to community waiver programs and Programs of All-Inclusive Care for the Elderly ... -
Economic return of clinical trials performed under the pediatric exclusivity program.
(JAMA, 2007-02-07)CONTEXT: In 1997, Congress authorized the US Food and Drug Administration (FDA) to grant 6-month extensions of marketing rights through the Pediatric Exclusivity Program if industry sponsors complete FDA-requested pediatric ... -
Effects of teaching on hospital costs.
(J Health Econ, 1983-03)This study estimates effects of undergraduate and graduate medical education on hospital costs, using a national sample of 367 U.S. community hospitals observed in 1974 and 1977. Data on other cost determinants, such as ... -
Fish is food--the FAO's fish price index.
(PLoS One, 2012)World food prices hit an all-time high in February 2011 and are still almost two and a half times those of 2000. Although three billion people worldwide use seafood as a key source of animal protein, the Food and Agriculture ... -
Reduced length of hospital stay in colorectal surgery after implementation of an enhanced recovery protocol.
(Anesth Analg, 2014-05)BACKGROUND: Enhanced recovery after surgery (ERAS) is a multimodal approach to perioperative care that combines a range of interventions to enable early mobilization and feeding after surgery. We investigated the feasibility, ... -
Returns to R&D on new drug introductions in the 1980s.
(J Health Econ, 1994-12)This study finds that the mean IRR for 1980-84 U.S. new drug introductions is 11.1%, and the mean NPV is 22 million (1990 dollars). The distribution of returns is highly skewed. The results are robust to plausible changes ... -
Spending on postapproval drug safety.
(Health Aff (Millwood), 2006-03)Withdrawals of high-profile pharmaceuticals have focused attention on post-approval safety surveillance. There have been no systematic assessments of spending on postapproval safety. We surveyed drug manufacturers regarding ... -
The cost of visual impairment: purposes, perspectives, and guidance.
(Investigative ophthalmology & visual science, 2010-04) -
The distribution of sales revenues from pharmaceutical innovation.
(Pharmacoeconomics, 2000)OBJECTIVE: This report updates our earlier work on the returns to pharmaceutical research and development (R&D) in the US (1980 to 1984), which showed that the returns distributions are highly skewed. It evaluates a more ... -
The price of innovation: new estimates of drug development costs.
(J Health Econ, 2003-03)The research and development costs of 68 randomly selected new drugs were obtained from a survey of 10 pharmaceutical firms. These data were used to estimate the average pre-tax cost of new drug development. The costs of ...
